Do all patients initiating omalizumab need to have it administered in a healthcare setting?

In the trials, all cases of anaphylaxis were on first administration--suggesting it is not intrinsic to drug and is more likely because you are giving it to a group of people who may be more susceptible to anaphylaxis in general. FDA has cleared at home use, so my general approach in a patient without anaphylaxis history is to suggest they have their first dose in an office, then subsequently at home. I usually suggest that to be extra safe they do so with an EpiPen available and when they are n...